• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [520 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (advanced NSCLC with RET fusion) - Benefit assessment according to § 35a SGB V]
2022 NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022 National Institute for Health and Care Excellence (NICE) Microwave ablation for primary or metastatic cancer in the lung. NICE interventional procedures guidance 716
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2022 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tepotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022 Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2021 Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)
2021 Adelaide Health Technology Assessment (AHTA) Small gene panel testing for non-small cell lung carcinoma
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (malignant pleural mesothelioma) - Addendum to Commission A21-89]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2021 Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021 Norwegian Institute of Public Health (NIPH) [Evaluation of PD-L1 assays in urothelial carcinoma: a rapid HTA]
2021 National Institute for Health and Care Excellence (NICE) Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Addendum to Commission A20-87]
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2021 Austrian Institute for Health Technology Assessment (AIHTA) HSR in Oncology: patients with non-small cell lung cancer treated with anti-PD-1/PD-L1 therapy in real-world practice. A pilot project in cooperation with Tirol Kliniken GmbH & KAGes
2021 National Institute for Health and Care Excellence (NICE) Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 705
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 713
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (NSCLC) - Addendum to Commission A20-116]
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC) - Addendum to Commission A20-118]
2021 National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Selpercatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: creation and characterization of a Québec lung cancer patient cohort using clinical administrative data]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V]
2020 Malaysian Health Technology Assessment (MaHTAS) Diagnostic approaches to solitary pulmonary nodule (SPN)
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020 National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lung cancer screening using low-dose computed tomography]
2020 Institut national d'excellence en sante et en services sociaux (INESSS) [Summary: investigation, treatment and follow-up algorithm - lung cancer]
2020 Ontario Health Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: A Health Technology Assessment
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2020 Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiation therapy in liver and lung tumors]
2020 Institute for Clinical Effectiveness and Health Policy (IECS) [Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 618
2020 National Institute for Health and Care Excellence (NICE) Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 628
2020 National Institute for Health and Care Excellence (NICE) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2020 National Institute for Health and Care Excellence (NICE) Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 638
2020 National Institute for Health and Care Excellence (NICE) Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 643
2020 The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice reassessment osimertinib (Tagrisso®)
2020 National Institute for Health and Care Excellence (NICE) Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2020 National Institute for Health and Care Excellence (NICE) Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2020 National Institute for Health and Care Excellence (NICE) Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2020 National Institute for Health and Care Excellence (NICE) Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 662
2020 Malaysian Health Technology Assessment (MaHTAS) Transbronchial cryobiopsy for lung biopsy in interstitial lung disease
2020 European Network for Health Technology Assessment (EUnetHTA) Lung cancer screening in risk groups
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with nab-paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2020 Austrian Institute for Health Technology Assessment (AIHTA) [Lung cancer screening in risk groups]
2020 Austrian Institute for Health Technology Assessment (AIHTA) Lung cancer screening in risk groups: a review-update of the economic evidence (Part II)
2019 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Validity, clinical utility and safety of the next-generation sequencing (NGS) genomic platform FoundationOne® in non-small cell lung cancer and other solid tumors]
2019 NIHR Health Technology Assessment programme Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019 National Institute for Health and Care Excellence (NICE) Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. NICE technology appraisal guidance 571
2019 National Institute for Health and Care Excellence (NICE) Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 584
2019 National Institute for Health and Care Excellence (NICE) Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 595
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (non-small cell lung cancer) - Addendum to Commission A18-69]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of low-dose computed tomography lung cancer screening]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (squamous non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report]
2019 European Network for Health Technology Assessment (EUnetHTA) Robot-assisted surgery in thoracic and visceral indications
2019 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [PET/CT scan for solitary pulmonary nodule and non-small cell lung cancer]
2018 NIHR Health Technology Assessment programme Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (non-small-cell lung cancer) - Addendum to Commission A17-67]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Stereotactic body radiotherapy for lung cancer]
2018 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC)
2018 National Institute for Health and Care Excellence (NICE) Ceritinib for untreated ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 500
2018 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018 Institute for Clinical Effectiveness and Health Policy (IECS) [Osimertinib in lung cancer]
2018 National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 520
2018 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
2018 National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529